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ABSTRACT 
Objective: To perform an in vitro equivalence study of naproxen sodium from six immediate release oral dosage forms under the hydrodynamic 
environments generated by the flow-through cell method and the USP paddle apparatus. 
Methods: Dissolution method was properly validated according to standard criteria. Dissolution profiles of all formulations were carried out with 
an automated flow-through cell (laminar flow at 16 ml/min with 22.6 mm cells) and the USP Apparatus 2 (50 rpm). 0.1 M phosphate buffer pH 7.4 
at 37.0±0.5 °C was used as the dissolution medium. Spectrophotometric determination of drug at 332 nm was carried out during 45 min. Dissolution 
profiles were compared with model-dependent and independent approaches. 
Results: Significant difference with model-independent parameters, mean dissolution time and dissolution efficiency, using both USP apparatuses, 
were found (*P<0.05). Best fitting of dissolution data was obtained using the sigmoidal model (R2>0.99). Only with the flow-through cell method 
linear regression between mean dissolution time and t63.2%
Conclusion: The 
 values was significant (*P<0.05). 
study reveals significant differences in dissolution rate and a great variability for all naproxen sodium tablets when the USP paddle 
apparatus is used. 
Keywords: Naproxen sodium, Flow-through cell method, Immediate-release generic products. 
The alternative dissolution test with the flow-through cell method allows obtaining reliable data which facilitates in vitro 
equivalence respect the reference product dissolution behavior. 
 
INTRODUCTION 
Dissolution testing is official evidence used worldwide for 
demonstrating an adequate in vitro drug release from immediate-
release solid dosage forms. Many of these drug products commercially 
exist as generic products. Generic drugs production represents savings 
for patients and hospitals; however generic formulations should be 
evaluated periodically to ensure adequate therapeutic effect. 
Dissolution is essential for predicting in vivo bioavailability and in 
some cases an excellent tool to determine bioequivalence and assure 
interchangeability. Previous studies have shown that despite most 
drug products meet pharmacopoeia dissolution criteria, some generics 
differed in their dissolution profiles when comparing with their 
branded counterparts which questions the interchangeability between 
them or even among generics [1]
Due to the high cost of bioequivalence studies, Guidelines for 
Industry-based on Food and Drug Administration (FDA) Bio 
pharmaceutical Classification System (BCS) have established the 
criteria by which bioequivalence studies can be replaced by in vitro 
dissolution studies 
. 
[2]. This waiver is based mainly on the fulfillment 
of similarity factor (f2) criteria between the dissolution profiles of 
test and reference product in different dissolution media (with pH 
values of physiological relevance) and compliance with related 




Fig. 1: Chemical structure of naproxen sodium 
 
Naproxen is a poorly soluble non-steroidal anti-inflammatory drug 
(NSAID) used to treat arthritis, post-operative pain, headache and 
musculoskeletal pain [4]. Because of its low water solubility, sodium 
salt is preferred to its acidic form, fig. 1. The drug is marketed in 
different doses as over-the-counter (OTC) products. Considering the 
criteria of BCS, naproxen sodium has been classified as a Class II 
drug [5]. Class II drugs (low solubility/high permeability) 
Since 2005, Mexican Health Authorities established the requirement 
to demonstrate bioequivalence between naproxen sodium immediate-
release solid dosage forms (generics) with regard to the reference 
product in order to consider test products eligible to be included in the 
"Interchangeable Generic Medicines Catalog" 
are 
expected to have a dissolution-limited absorption and a significant in 
vitro/in vivo correlation (IVIVC) should be expected using a well-
designed in vitro dissolution test. 
[6]. Dissolution profiles 
between drug products must comply with the f2 criteria (50-100). 
Official dissolution test for naproxen sodium tablets is described in the 
United States Pharmacopoeia (USP) [7]. The method indicates the use 
of USP paddle apparatus (USP Apparatus 2) at 50 rpm and 900 ml of 
0.1 M phosphate buffer pH 7.4 at 37.0±0.5 °C as the dissolution 
medium. Under these conditions, not less than 80% of the drug should 
be dissolved in 45 min (Q≥80%). However, to date there is no 
information confirming adequate in vitro correlation with in vivo 
results obtained under these conditions. 
An alternative dissolution system to the conventional USP basket 
(USP Apparatus 1) and paddle apparatus (USP Apparatus 2), used to 
document the in vitro dissolution performance of immediate-and 
extended-release formulations, is the flow-through cell method (USP 
Apparatus 4) [8, 9]. Their advantages over the USP Apparatus 1 and 
2 have been widely demonstrated especially with poorly soluble 
drugs [10, 11]. USP Apparatus 4 has a continuous extraction of the 
drug, simulating the absorption into the systemic circulation, 
generating intermittent flow of dissolution medium into the cell 
where the dosage form is placed [12]. It is possible to use the USP 
Apparatus 4 as an open system that can operate under sink 
conditions which facilitate the dissolution of drugs with limited 
solubility, as well as changing the dissolution medium within a range 
of physiological pH values throughout the test [13]. The flow-
through cell method better simulates the hydrodynamic 
environment that is found inside the gastrointestinal tract. Previous 
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information of some poorly soluble drugs shows that in vitro data 
obtained in the USP Apparatus 4 better predicts or correlates with 
their in vivo performance [14, 15]. The flow-through cell method has 
proved to be useful in the development of a more discriminating 
dissolution method for albendazole and carbamazepine tablets than 
the official one USP paddle apparatus [16, 17]. Despite the 
advantages of the USP Apparatus 4, information about dissolution 
behavior of naproxen sodium tablets under the hydrodynamic 
environment generated by the flow-through cell method is scarce. 
Previously, IVIV evaluation of commercial dosage forms of naproxen 
(250 mg) revealed that disintegration time and dissolution 
parameters failed to give the true indication of bioavailability [18]. In 
vitro studies were carried out with the USP basket apparatus at 100 
rpm and phosphate buffer pH 7.4 as the dissolution medium. 
Moreover, quality evaluation of some Mexican drug products 
containing naproxen sodium was also reported [19]. In the study, 
routine quality control tests were performed according to USP 
procedures. The authors reported that despite all drug products 
studied met the USP quality standards, the dissolution profiles showed 
significant differences among them and even between different lots of 
the same product. 
The main objective in this in vitro equivalence study was to evaluate 
the release performance of naproxen sodium from immediate-
release generic products sold in the local market to investigate the 
dissolution performance of this widely use NSAID under the 
hydrodynamic environment generated by the flow-through cell 
method. Results obtained were compared with the official USP 
paddle apparatus. 
MATERIALS AND METHODS 
Materials 
Naproxen sodium tablets (550 mg) of six immediate-release oral 
dosage forms from the Mexican market were used. Generic products 
(designated by letters: A, B, C, D and E) were compared with Flanax® 
(Bayer Bitterfeld GmbH Mexico) as the reference product 
(designated with letter R), Sodium phosphate monobasic and dibasic 
crystals were purchased from J. T. Baker-Mexico. Naproxen sodium 
standard was purchased from Sigma-Aldrich Co. (St. Louis MO, USA). 
Content uniformity and assay 
Content uniformity and assay tests were performed on all products, 
according the procedures described in the USP [7]. 
Analytical method validation 
The analytical method used was validated according to Mexican 
regulations [20]. To demonstrate the linearity of the 
spectrophotometric system, six calibration curves with five different 
naproxen sodium concentrations (range 12.5–200 µg/ml) were 
prepared in the dissolution medium (0.1 M phosphate buffer pH 7.4) 
and analyzed at 332 nm. Data obtained were fitted by linear 
regression and the coefficients of regression, regression analysis of 
variance (ANOVA) and 95% confidence interval (CI95%) for the value 
of the intercept were calculated. The system precision was 
demonstrated by calculating the percentage relative standard 
deviation (RSD): [((standard deviation)/mean) × 100] at each 
concentration level. 
Method linearity (drug with excipients) was determined by the 
added standard method. Twenty tablets were accurately weighed 
and crushed in a mortar; then, quantities of powder of naproxen 
sodium tablets plus a quantity of naproxen sodium standard (10 mg) 
to finally give the equivalent of 40, 60, 80, 100 and 120% of the dose 
were separately dissolving in 900 ml of 0.1 M phosphate buffer pH 
7.4 at 37.0±0.5 ºC. The USP paddle apparatus at 50 rpm was used. At 
45 min the amount of naproxen sodium dissolved in each vessel was 
calculated with reference to a standard calibration curve prepared 
on the day of the experiment. Each determination was performed by 
triplicate. In order, to evaluate the linearity of the method, data were 
plotted (dissolved amount vs added amount) and determination 
coefficient (R2), CI95% for the slope and intercept and regression 
ANOVA was calculated. The accuracy was evaluated by calculating 
the CI95% of the average percentage of naproxen sodium recovered 
from known added amount of drug. The precision was determined 
by calculating the RSD for the percentage of drug dissolved 
(repeatability). To evaluate the random events effect on the 
analytical method precision a homogeneous sample of tablets 
powder, equivalent to 100% of the dose was analyzed by triplicate, 
by two analysts in two different days (reproducibility); results 
obtained were analyzed by two-way ANOVA. Differences were 
considered significant if *P<0.05. 
Dissolution profiles 
USP paddle apparatus 
Dissolution profiles of naproxen sodium were determined according 
to USP test [7] in an automated USP Apparatus 2 (Sotax AT-7 Smart, 
Switzerland) with a piston pump (Sotax CY7-50, Switzerland). An 
UV/Vis spectrophotometer with 1 mm flow cells (Perkin Elmer 
Lambda 35, USA) was used. All equipment and data generated were 
controlled by specific software designed by Sotax. Naproxen sodium 
tablets were sprinkled on 900 ml of 0.1 M phosphate buffer pH 7.4 at 
37.0±0.5 °C as the dissolution medium. Rotational speed of 50 rpm 
was tested. Sequential sampling using 0.45 µm nitrocellulose filters 
(Millipore®) was performed over 45 min at regular 5 min intervals 
with 12 replicates. The amount of naproxen sodium dissolved was 
determined with a standard calibration curve at 332 nm. 
Dissolution profiles of naproxen sodium were obtained in an 
automated USP Apparatus 4 (Sotax CE6, Sotax AG, Switzerland) with 
22.6 mm cells (i.d.) and a piston pump (Sotax CY7-50, Sotax AG, 
Switzerland). Laminar flow (with a bed of 6 g of glass beads) was used. 
The degassed dissolution medium, 0.1 M phosphate buffer pH 7.4 at 
37.0±0.5 °C was pumped at a flow rate of 16 ml/min. An open system 
was used, without recycling the dissolution medium. Sequential 
sampling using nitrocellulose filters was set at regular 5 min intervals 
over 45 min, with 12 replicates. The amount of naproxen sodium 
dissolved was determined in an UV/Vis spectrophotometer with 1 mm 
cells (Perkin Elmer Lambda 10, USA) at 332 nm. For every trial, a 
standard calibration curve was prepared. 
Flow-through cell method 
Data analysis 
Dissolution data of naproxen sodium were used to calculate model-
independent parameters: mean dissolution time (MDT) and 
dissolution efficiency (DE). Values for generic products were 
compared with the values of the reference product by ANOVA, 
followed by Dunnett’s or Dunnett’s T3 multiple comparisons test as 
appropriate. For comparison of dissolution profiles using model-
dependent approach, dissolution data were fitted to Higuchi, Hixson-
Crowell and Korsmeyer-Peppas’ kinetic models [21]. The model with 
the highest determination coefficient (R2 adjusted) and the minimum 
Akaike information criterion (AIC) was chosen as the best fit. Data 
analysis was carried out using the Excel add-in DDSolver program 
[22]. Additionally, dissolution data were adjusted to a non-linear 
equation (sigmoidal model) with Sigma Plot software (version 11.0) 
and with the derived parameters (a, b and x0) from the adjustment 
to this kinetic model t63.2% values were calculated. 
RESULTS AND DISCUSSION 
Content uniformity and assay 
All drug products were within USP limits. The percentages of naproxen 
sodium on the content uniformity test ranged from 90.90
 
 to 105.80% 
and the assay test was between 91.61 to 104.66%, table 1. 
Table 1: Content uniformity and assay results. Mean, n = 10 
Product Content uniformity (min-max) Assay (%) 
R 95.26–96.49 96.10 
A 91.96–94.83 93.85 
B 90.90–92.33 91.61 
C 91.53–94.22 93.04 
D 101.73–105.80 104.66 
E 94.18–99.65 96.72 
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Method validation 
The mean regression equation from six standard calibration curves 
was: y = 0.00653x+0.01277. Linear regression was significant 
(R2>0.99; *P<0.05). The CI95% estimated the value of the intercept 
was–0.0024 to 0.0279. The highest RSD value was 2.62% for the five 
concentrations levels evaluated. 
The analytical method validation was carried out with all drug 
products used in the present in vitro equivalence study however; 
as an example and in order that method validation is not the 
main objective of this work, only the reference product data are 
shown. The regression equation to assess the method linearity 
was y = 0.9277x–11.28 (R2>0.98; *P<0.05). The CI 95% estimated 
for the slope was 0.805 to 1.050 and–65.10 to 42.53 for the 
intercept. The method accuracy was 94.87% with a CI 95%  of 
89.55 to 100.19%. The RSD value calculated to assess the 
method precision was 3.0% and the two-way ANOVA showed no 
significant differences in drug dissolved between days and 
analysts (*P>0.05). All generic products also met national 
standard validation criteria [20]. 
Dissolution profiles 
Dissolution profiles of naproxen sodium from all immediate-
release products, in both USP Apparatuses, 
 
are shown in fig. 2. 
Considering a single point specification (Q≥80% in 45 min) all 
drug products met the pharmacopoeia dissolution criterion 
excepting product-A in USP paddle apparatus (72.62%). Under the 
hydrodynamic environment generated by the USP Apparatus 2, all 
drug products showed different dissolution rates and the maximal 
percent dissolved at 45 min were 87.16% (product-C). On the 
other hand, and with use of the flow-through cell method, three 
generic products showed comparable dissolution performance to 
the reference (A, D and E) and percentage dissolved in 45 min was 
between 88.17 to 102.44%. 
 
Fig. 2: In vitro dissolution profiles of naproxen sodium from all 
studied drug products. Error bars were omitted for clarity. The 
straight line shows Q=80%. Mean, n = 12 
Using USP paddle apparatus, high variability in all dissolution data 
was observed (RSD>20% at 5 min and>10% from 10 to 30 min). For 
this reason, similarity factor f2 was not calculated. With the flow-
through cell method, RSD of product-B and E were also out of 
criterion and comparison of dissolution profiles with similarity 
factor f2 was calculated only for product-A, C and D, table 2. Only 
dissolution profiles for product-A and D were similar to reference 
dissolution profile (f2>50). 
 
Table 2: Similarity factor f2. Due to high variability only three 
data were calculated 
Product USP paddle apparatus Flow-through cell method 
A - 60.10 
B - - 
C - 46.81 
D - 84.48 
E - - 
 
Differences in dissolution rate of naproxen sodium for all drug 
products were found by both methods used. It is known that 
naproxen oral dosage forms are widely used in inflammatory 
diseases such as acute gout and rheumatoid arthritis. The absorption 
of drugs with poor aqueous solubility is dissolution rate limited and 
therefore, they exhibit poor bioavailability as well as fluctuation in 
blood concentrations [23]. Razdan et al. conducted an evaluation of 
naproxen oral dosage forms [18]. Five commercial products (250 mg 
tablets) were administered to healthy volunteers and dissolution 
tests were carried out with the USP basket apparatus at 100 rpm 
and phosphate buffer pH 7.4 as the dissolution medium. Authors 
reported that dissolution parameters, t50% and k values, did not 
correlated with in vivo parameters as area under the curve and Cmax, 
concluding that the dissolution tests do not detect differences in 
absorption rate (i.e. differences in bioavailability). It is accepted that 
dissolution conditions in USP basket apparatus at 100 rpm are 
equivalent to conditions generated by USP paddle apparatus at 50 
rpm, so it can be expected that current pharmacopoeia specifications 
for naproxen sodium tablets dissolution test should not either 
adequately detect differences in drug absorption rate. 
With the flow-through cell method and at the beginning of the 
dissolution test, all drug products showed a slower dissolution rate 
than that found with the USP paddle apparatus. Langenbucher et al. 
expressed that this kind of behavior can be explained by the 
hydrodynamic conditions that characterize the USP Apparatus 4, 
where no agitation mechanisms exists and the dosage form and the 
drug particles are continuously exposed to a uniform laminar flow, 
similar to the natural environment of the gastrointestinal tract, causing 
a different dissolution pattern [24]. In the flow-through cell method, 
cell size, glass beads and flow rate are critical factors to form this 
dissolution pattern. In the present, in vitro equivalence study, flow rate 
of 16 ml/min, suggested in European and United States 
Pharmacopeias, was used [25]. Fotaki et al. reported that the intestinal 
fluid axial velocity has been estimated to be approximately of 1.5 
cm/min and the fluid flow inside the 22.6 mm cells is 4 cm/min when 
the flow rate of dissolution medium is 16 ml/min [26]. Then, 4 cm/min 
as intestinal fluid axial velocity formed by the experimental conditions 
described above is close to physiological parameters. 
Model-independent comparisons 
 
Percentage dissolved in 45 min and model-independent parameters: 
MDT and DE mean values±standard error medium (SEM), in both 
USP Apparatuses, are shown in table 3. With the USP paddle 
apparatus, only value of percentage dissolved in 45 min of product-A 
was different from value of product-R (*P<0.05). Additionally with 
USP Apparatus 2, significant differences in all MDT and DE values 
were found (*P<0.05). Using the flow-through cell method, the 
percentage dissolved in 45 min significantly differed for product-A, 
B and E from product-R (*P<0.05), while no differences between 
product-D and product-R were found. 
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Table 3: Dissolution parameters of naproxen sodium. Mean±SEM, n = 12 
USP Apparatus Product % Diss. at 45 min MDT (min) DE (%) 
2 R 87.11±1.18 11.59±0.55 64.71±1.54 
A 72.62±1.50* 15.18±0.50* 48.04±0.95* 
B 87.07±0.84 20.77±0.44* 46.87±0.91* 
C 87.16±1.57 7.45±0.32* 72.73±1.49* 
D 84.41±2.04 16.11±0.45* 54.12±1.35* 
E 84.77±2.30 15.35±0.35* 55.82±1.57* 
4 R 100.55±0.79 16.81±0.19 62.98±0.62 
A 91.79±1.14* 14.04±0.26* 63.16±1.05 
B 88.17±2.08* 21.85±0.22* 45.35±1.12* 
C 96.98±0.87 10.98±0.16* 73.31±0.60* 
D 102.44±1.01 16.83±0.14 64.11±0.46 
E 89.72±1.0* 14.42±0.44* 61.01±1.25 
 
 MDT: mean dissolution time; DE: dissolution efficiency; *P<0.05 
With the flow-through cell method drug products showed slower 
dissolution rate than the USP paddle apparatus at the beginning of 
the test, but at the end all products reached a higher percentage 
dissolved than with the official method and generic products that 
significant differ in dissolution extent compared with the reference 
product, met the USP specification (Q≥80% in 45 min) when using 
the alternative USP 4 method. 
The dissolution data from generic products were also compared 
with the reference product by model-independent parameters MDT 
and DE. MDT is the time interval necessary to dissolve 63.2% of the 
drug present in the pharmaceutical dosage form and it was 
calculated according to statistical moment’s theory. On the other 
hand, DE is the area under the dissolution curve up to a certain time 
t, expressed as a percentage of the area of the rectangle described by 
100% dissolution in the same time; so while MDT is related to 
dissolution rate, DE relates to drug dissolution extent. These model-
independent parameters have been proposed as adequate 
parameters for some IVIVC levels [27]. IVIVC Level B is based on the 
comparison of parameters calculated by statistical moment’s theory 
as MDT is, while Level C requires the calculation of an in vitro 
parameter that expresses a global drug dissolution performance as 
is the case of DE. 
Model-dependent comparisons 
Considering established criteria to choose the best kinetic model 
(highest R2 adjusted and lowest AIC values) using the USP paddle 
apparatus, dissolution data of product-E adjusted to Higuchi’s 
equation and data for product-R and D to Hixson-Crowell’s model. 
The highest value of R2 adjusted being 0.9741. On the other hand, with 
the flow-through cell method all drug products adjusted to Hixson-
Crowell’s kinetics excepting product-B. Of these five drug products, 
the highest value of R2 adjusted
 
 was 0.9753. Is important to note that, 
with the use of USP Apparatus 4, the five drug products that meet 
the establish criteria adjusted to the same dissolution kinetics 
(Hixson-Crowell). Results are shown in table 4. 
 
Table 4: Criteria used for selection of best kinetic model. Mean, n = 12 
USP paddle apparatus Flow-though cell method 
Product Higuchi Hixson-Crowell Korsmeyer-Peppas Higuchi Hixson-Crowell Korsmeyer-Peppas 
 R2 adjusted 
R 0.8805 0.9148 0.8772 0.8936 0.9717 0.9518 
A 0.9606 0.7671 0.9797 0.8864 0.9709 0.9216 
B 0.7320 0.8900 0.9542 0.7704 0.9280 0.9838 
C 0.3547 0.5537 0.8635 0.8295 0.9604 0.9034 
D 0.9226 0.9741 0.9470 0.8769 0.9555 0.9349 




R 54.78 52.32 78.96 62.56 50.27 77.96 
A 39.69 55.46 54.14 61.39 48.80 80.30 
B 72.07 63.93 75.82 69.22 58.51 65.01 
C 67.28 61.45 72.19 64.82 51.47 81.98 
D 54.63 42.86 72.40 64.83 55.45 82.47 
E 45.70 49.00 71.70 60.50 46.54 78.85 
 
Naproxen adjusted data to some dissolution kinetic models has been 
reported by other authors. Azevedo de Mello et al. reported in vitro 
release of naproxen to Higuchi’s equation. Drug was loaded in poly-ε-
caprolactone, nanoparticles used for extending the pharmacological 
action and reducing the frequency of administration [28]. Dissolution 
studies were carried out in USP paddle apparatus at 100 rpm with 0.1 M 
phosphate buffer pH 7.4 as dissolution medium. Meanwhile, Guo et al. 
fitted dissolution profiles to Korsmeyer-Peppas’ model [4]. Naproxen 
was loaded in mesoporous silica materials (ideal materials for 
encapsulation of pharmaceutical drugs). Experiments were performed in 
USP paddle apparatus at 50 rpm and simulated intestinal fluid pH 6.8 
was used as dissolution medium. 
 
Due to high variability observed in adjusting the in vitro release data 
to these three widely used dissolution kinetic models, dissolution 
profiles comparison using a derived parameter of any one of these 
three dissolution models was not possible. Then, a non-linear 
adjustment was used as an alternative fitting method. 
Fig. 3: Influence of dissolution apparatus on the naproxen 
sodium release. Mean, n = 12 
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With the aim of comparing the drug release performance from the 
product-R in both dissolution systems, dissolution profiles of 
naproxen sodium are shown in fig. 3. 
Considering the tendency of experimental results, dissolution data 







Where x is time point and y is percentage of drug dissolved at that 
time. Despite the difference in the hydrodynamic environment 
generated by the flow-through cell method and USP paddle 
apparatus, in both USP dissolution systems, equivalence in drug 
dissolution performance from the product-R was found. As 
dissolution rate of all generic products maintained the same 
dissolution pattern, dissolution data of these drug products were 
also adjusted with the sigmoidal equation. Results are shown in 
table 5. The data were adjusted to sigmoidal model allowed to obtain 
R2 values higher than 0.99. 
 
In this in vitro equivalence study, data fitting to sigmoidal model was 
performed without any physiological significance in order to find a 
mathematical equation that explains the dissolution data behavior 
and generates estimates closer to reality than the three conventional 
dissolution equations used. The purpose of using mathematical 
models to adjust dissolution results is that they facilitate the analysis 
and interpretation of observed data because they describe the 
dissolution profiles as a function of only a few model parameters 
that can be statistically compared [29]. 
Table 5: R2 values and parameters derived to the adjustment of dissolution data to sigmoidal model. M
USP Apparatus 
ean, n = 12 
Product R a 2 b x0 
2 R 0.9931 88.95 7.06 10.41 
A 0.9933 81.49 14.29 15.28 
B 0.9944 85.67 5.10 19.96 
C 0.9941 87.55 4.21 6.24 
D 0.9957 84.27 7.58 14.81 
E 0.9953 98.22 10.45 14.57 
4 R 0.9927 100.46 6.89 15.85 
A 0.9941 91.22 6.31 13.09 
B 0.9908 88.42 6.94 21.44 
C 0.9971 97.14 4.07 10.50 
D 0.9936 102.31 6.45 16.01 
E 0.9941 89.59 5.74 13.53 
 
Sigmoidal release is usually observed in press-coated or film-coated 
systems with tablets or pellets as substrate [30,31] and dissolution 
profiles with this release pattern has been reported by some 
authors. Wei et al. described the indomethacin release from pectin 
matrix tablets [30] and Kállai-Szabó et al. described the release of 
diclofenac sodium from layered and coated pellets [32]. Both are 
poorly soluble drugs with anti-inflammatory activity. Dissolution 
profiles of indomethacin were carried out in USP basket apparatus 
and diclofenac sodium with USP paddle apparatus. Both studies used 
100 rpm as agitation rate and water as the dissolution medium. The 
authors agree that this kind of release profile may be therapeutically 
beneficial for timed release even Wei et al. reported that for diseases 
influenced by circadian rhythms such as heart diseases, asthma and 
arthritis; incremental release rate may be helpful to prevent 
exacerbation of nocturnal or early morning symptoms [30]. On the 
other hand, Jantratid et al. Also used diclofenac sodium as model 
drug [15]. They reported sigmoidal performance of drug from an 
oral modified-release pellet dosage form using USP basket (50 rpm) 
and paddle apparatus (75 or 125 rpm) with buffer solution pH 6.8 as 
dissolution medium and USP Apparatus 3 (10 dpm) and flow-
through cell method (22.6 mm diameter test cells) with bio relevant 
dissolution medium. Authors reported that pharmacopoeia 
dissolution test was not able to predict food effects and biorelevant 
dissolution methodology is generally appropriate for the evaluation 
of the in vivo performance of drug with the USP Apparatus 4. It is 
important to note that almost all formulations used in the present in 
vitro study were film-coated dosage forms, justifying the observed 
behavior. 
Other parameters used to characterize drug release profile are tx% 
and sampling time. The tx% corresponds to the time necessary to the 
release of a determined percentage of drug (e. g., t20%,  t50%,  t90%) and 
sampling time corresponds to the amount of drug dissolved in that 
time (e. g., t20 min,  t50 min,  t90 min). Pharmacopeias very frequently use 
this parameter as an acceptance limit of the dissolution test (e. g., t45 
min≥80%) [33]. In order to find for a relationship between MDT (time 
to achieve 63.2% of dose dissolved) and a data derived from the 
sigmoidal model adjustment that represents the same extent of drug 
dissolution, t63.2% values were calculated with data reported in table 
5. Fig. 4 shows t63.2% values vs MDT values, in both USP apparatuses, 
Linear regressions were calculated (R2=0.5442 vs 0.9550; USP 
paddle apparatus and flow-through cell method, respectively) and 
only with the use of USP Apparatus 4 less variation, high R2
 
 value 
and a significant linear regression was found (*P<0.05). 
 
Fig. 4: Linearity between MDT and t63.2% values of naproxen 
sodium from all studied products. Mean, n = 12 
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The correlation found between t63.2% (model-dependent parameter) 
and MDT data (model-independent parameter) for all drug products 
shows a uniformity between both approaches only with dissolution 
tests in the USP Apparatus 4. Hydrodynamic environment generated 
by the vessels system did not adequately characterize in vitro drug 
release from drug products studied. 
According data reported by Razdan et al. dissolution conditions of 
naproxen tablets in USP basket apparatus at 100 rpm and phosphate 
buffer pH 7.4 failed to find any correlation between IVIV parameters 
implying that these conditions are not able to detect products having 
different absorption rate [18]. It is important to emphasize that in 
vitro condition used by Razdan et al. are similar to those generated 
by USP paddle apparatus at 50 rpm and these conditions are used as 
quality control test and it is not feasible to find a significant IVIVC 
with current pharmacopoeia method for naproxen tablets [18]. 
The results found in the present in vitro equivalence study prove the 
possibility that a low in vivo dissolution rate might be the cause of lack of 
bioequivalence. The flow-through cell method is an apparatus that better 
reflects the in vivo environment of the gastrointestinal tract and it is an 
appropriate option to find a significant IVIVC. Several authors have 
reported on this equipment a better estimate of an absorption rate 
(which is a better predictor of in vivo dissolution) of cilostazol and 
diclofenac sodium [14, 15] both poorly soluble drugs. 
The results suggest that laboratories seeking significant IVIVC with 
naproxen sodium formulations of this type (coated tablets) are more 
likely to be found with in vitro studies using the flow-through cell 
method and not with conventional pharmacopoeia tests that use USP 
paddle apparatus. The hydrodynamic characteristics that USP 
Apparatus 4 generates (and supplemented with in vitro information 
from different commercial drug products) allow dissolution results 
with less variation comparing with results obtained with the 
conventional vessels system. Studies based on computational fluid 
dynamics revealed the complexity of the fluid flow in the paddle 
apparatus and the chaotic aspects of the hydrodynamics 
environment that this apparatus generates [34, 35]. It is better to 
look similarity with the dissolution profile of the reference product 
using the flow-through cell method since the formulations may not 
be the problem. The choice of the hydrodynamic environment under 
which the drug release is evaluated is a key factor in finding 
significant IVIVC. One supports interpreting dissolution data from 
the USP Apparatus 4 was carried out by D’Arcy et al. where 
computational fluid dynamics were used to simulate the 
hydrodynamics and mass transfer features in the flow-through cell 
apparatus [36] and by Kakhi et al. that examines the dissolution 
apparatus from an engineering fluid mechanics viewpoint [37]. 
The comparative in vitro dissolution study using the USP paddle 
apparatus and the flow-through cell method reveals significant 
differences in dissolution rate of naproxen sodium from Mexican 
immediate-release generic products and by the worldwide use of 
naproxen generics this could be replicated in other countries. It is 
essential to find dissolution conditions that allow discriminate 
between products and that in vitro results have greater ability to 
significant correlate with in vivo parameters. It is possible 
mentioned that generic products with differences in dissolution 
performance are candidates to show bioavailability differences and 
therefore it will be necessary to evaluate their in vivo performance 
before considering being interchangeable with the reference 
product. 
The in vitro equivalence study reveals significant differences in 
dissolution rate of naproxen sodium from immediate-release generic 
products, showing a great variability between unit dosage forms 
when the USP paddle apparatus is used. The alternative flow-
through cell method allows to obtain reliable data which could be 
useful when searching for an in vitro dissolution method that 
adequately reflects in vivo performance. 
CONCLUSION 
ACKNOWLEDGMENT 
The authors are thankful to QFB Adriana Desireé Pineda Domínguez 
for her technical assistance. 
CONFLICT OF INTERESTS 
Declared None 
REFERENCES 
1. Al Almeri MN, Nayuni N, Anuil Akumar KG, Perrett D, Tucker A, 
Johnston A. The differences between the branded and generic 
medicines using solid dosage forms: in-vitro dissolution testing. 
Results Pharma Sci 2012;2:1−8. 
2. Food and Drug Administration. Guidance for industry: Waiver 
on in vivo bioavailability and bioequivalence studies for 
immediate-release solid oral dosage forms based on a 
biopharmaceutics classification system; 2000. 
3. Lennernäs H, Abrahamsson B. The use of biopharmaceutical 
classification of drugs in drug discovery and development: 
current status and future extension. J Pharm Pharmacol 
2005;57:273–85. 
4. Guo Z, Liu X, Ma L, Li J, Zhang H, Gao Y, et al. Effects of particle 
morphology, pore size and surface coating of mesoporous silica 
on naproxen dissolution rate enhancement. Colloid Surf B 
2013;101:228−35. 
5. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, 
Lennernäs H, Hussain AS, et al. Molecular properties of the 
WHO essential drugs and provisional biopharmaceutical 
classification. Mol Pharm 2004;1:85–96. 
6. ACUERDO por el que se adiciona y modifica la relación de 
especialidades farmacéuticas susceptibles de incorporarse al 
catálogo de medicamentos genéricos intercambiables. Diario 
Oficial de la Federación; 2005. Available from: URL: 
http://www.salud.gob.mx/unidades/cdi/nom/compi/a11020
5.html [Last accessed 02 Apr 2015]. 
7. United States Pharmacopeia and national formulary USP 37-NF 
32; The United States Pharmacopeial Convention, Inc: Rockville 
MD; 2014. 
8. Singh I, Aboul-Enein HY. Advantages of USP Apparatus IV 
(flow-through cell apparatus) in dissolution studies. J Iran 
Chem Soc 2006;3:220–2. 
9. Qui S, Wang K, Li M. In vitro dissolution studies of immediate-
release and extended-release formulations using flow-through 
cell apparatus 4. Dissolution Technol 2014;21:6-
10. Sunesen VH, Pedersen BL, Kristensen HG, Müllertz A. In vivo in 
vitro correlations for a poorly soluble drug, danazol, using the 
flow-through dissolution method with biorelevant dissolution 
media. Eur J Pharm Sci 2005;24:305–13. 
15. 
11. Szymanska E, Winnicka K. Comparison of flow-through cell and 
paddle methods for testing vaginal tablets containing a poorly 
water-soluble drug. Trop J Pharm Res 2013;12:39–44. 
12. Emara LH, Emam MF, Taha NF, El-Ashmawy AA, Mursi NM. In-
vitro dissolution study of meloxicam immediate release 
products using flow through cell (USP apparatus 4) under 
different operational conditions. Int J Pharm Pharm Sci 
2014;6:254−60. 
13. Fotaki N, Reppas C. The flow through cell methodology in the 




Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M et 
al. In vitro-in vivo correlation for wet-milled tablet of poorly 
water-soluble cilostazol. J Controlled Release 2008;130:29
15. Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, 
Dressman JB. Application of biorelevant dissolution tests to the 
prediction of in vivo performance of diclofenac sodium from an 
oral modified-release pellet dosage form. Eur J Pharm Sci 
2009;37:434−41. 
−37. 
16. Hurtado M, Vargas Y, Domínguez-Ramírez AM, Cortés AR. 
Comparison of dissolution profiles for albendazole tablets using 
USP Apparatus 2 and 4. Drug Dev Ind Pharm 2003;29:777−84. 
17. Medina JR, Salazar DK, Hurtado M, Cortés AR, Domínguez-
Ramírez AM. Comparative in vitro dissolution study of 
carbamazepine immediate-release products using the USP 
paddles method and the flow-through cell system. Saudi Pharm 
J 2014;22:141−7. 
18. Razdan BK, Nagaraja NV. Evaluation of dosage forms: studies 
on commercial tablet dosage forms of naproxen. Pharm 
Pharmacol Commun 1998;4:253−6. 
Medina et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 7, 348-354 
354 
19. Hernández-Abad VJ, Castañeda-Hernández G, García-Jiménez S, 
Marroquín-Segura R, Sánchez-González E. Evaluation of the 
quality of four Mexican drug products containing sodium 
naproxen. J Clin Pharm Ther 2008;33:237
20. NOM-177-SSA1-2013, Norma Oficial Mexicana. Available from: 
URL: http://www.dof.gob.mx/nota_detalle. 
php?codigo=5314833&fecha=20/09/2013 [Last accessed 02 
Apr 2015]. 
−42. 
21. Yuksel N, Kanik AE, Baykara T. Comparison of in vitro 
dissolution profiles by ANOVA-based, model-dependent and 
independent-methods. Int J Pharm 2000;209:57 −67. 
22. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DD Solver: an 
add-in program for modeling and comparison of drug 
dissolution profiles. AAPS J 2010;12:263
23. Mishra B, Sahoo J, Kumar Dixit P. Formulation and process 
optimization of naproxen nanosuspensions stabilized by 
hydroxy propyl methyl cellulose. Carbohydr Polym 
2015;127:300−8. 
−71. 
24. Langenbucher F, Benz D, Kurth W, Moller H, Otz M. 
Standardized flow-cell method as an alternative to existing 
pharmacopoeial dissolution testing. Pharm Ind 
1989;51:1276−81. 
25. Steffansen B, Brodin B, Und Nielsen C. editors. Molecular 
Biopharmaceutics. ULLA Pharmacy Series. Pharmaceutical 
Press; 2010. 
26. Fotaki N, Symillides M, Reppas C. In vitro versus canine data for 
predicting input profiles of isosorbide-5-mononitrate from oral 




Cardot JM, Beyssac E, Alrici M. In vitro-in vivo correlation: 




Azevedo de Mello V, Ricci-Júnior E. Encapsulation of naproxen 
in nanostructured systems: structural characterization and in 
vitro release studies. Quim Nova 2011;34:933
29. Adams E, Coomans D, Smeyers-Verbeke J, Massart DL. Non-
linear mixed effects models for the evaluation of dissolution 
profiles. Int J Pharm 2002;240:37−53. 
−9. 
30. Wei X, Sun N, Wu B, Yin C, Wu W. Sigmoidal release of 
indomethacin from pectin matrix tablets: effect of in situ 
crosslinking by calcium cations. Int J Pharm 2006;318:132 −8. 
31. Ito R, Golman B, Shinohara K. Design of multi-layer coated 
particles with sigmoidal release pattern. Chem Eng Sci 
2005;60:5415−24. 
32. Kállai-Szabó N, Luhn O, Bernard J, Kállai-Szabó B, Zelkó R, Antal 
I. Comparative dissolution study of drug and inert isomalt 
based core material from layered pellets. J Pharm Biomed Anal 
2014;98:339−44. 
33. Costa P, Sousa Lobo JM. Modeling and comparison of 
dissolution profiles. Eur J Pharm Sci 2001;13:123 −33. 
34. D’Arcy DM, Corrigan OI, Healy AM. Hydrodynamic simulation 
(computational fluid dynamics) of asymmetrically positioned 
tablets in the paddle dissolution apparatus: impact on 
dissolution rate and variability. J Pharm Pharmacol 
2005;57:1243−50. 
35. Ameur H, Bouzit M. 3D hydrodynamics and shear rates’ 
variability in the united states pharmacopeia paddle 
dissolution apparatus. Int J Pharm 2013;452:42 −51. 
36. D’Arcy DM, Liu B, Bradley G, Healy AM, Corrigan OI. 
Hydrodynamic and species transfer simulations in the USP 4 
dissolution apparatus: considerations for dissolution in a low 
velocity pulsing flow. Pharm Res 2009;27:246 −58. 
37. Kakhi M. Classification of the flow regimes in the flow-through 
cell. Eur J Pharm Sci 2009;37:531 −44. 
 
